Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.41 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061095 | 0.93 | SLC6A4 (0.48) | SLC6A4SLC6A2CETPSLC6A3HTR2A | |
| SCHEMBL13005616 | 0.89 | BCHE (0.40) | SLC6A4SLC6A2CETPSLC6A3HTR2A | |
| SCHEMBL13005641 | 0.85 | SLC6A4 (0.41) | SLC6A4SLC6A2CETPSLC6A3HTR2A | |
| SCHEMBL13005518 | 0.84 | CETP (0.40) | SLC6A4SLC6A2CETPSLC6A3HTR2A | |
| SCHEMBL13005520 | 0.82 | LMNA (0.37) | SLC6A4SLC6A2CETPSLC6A3 | |
| SCHEMBL13005504 | 0.82 | ALDH1A1 (0.36) | SLC6A2CETPSLC6A3RIPK1 | |
| SCHEMBL13005507 | 0.82 | TAAR1 (0.34) | CETPCYP2D6 | |
| SCHEMBL13005500 | 0.82 | GABRA1 (0.39) | CETP | |
| SCHEMBL13005522 | 0.82 | CETP (0.36) | CETP | |
| SCHEMBL13005530 | 0.82 | TAAR1 (0.48) | CETPHTR2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |